BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 20479932)

  • 1. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
    Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
    PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
    Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
    Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
    Linn DE; Bronson RT; Li Z
    PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
    Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
    Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deregulation of an imprinted gene network in prostate cancer.
    Ribarska T; Goering W; Droop J; Bastian KM; Ingenwerth M; Schulz WA
    Epigenetics; 2014 May; 9(5):704-17. PubMed ID: 24513574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
    Zong Y; Xin L; Goldstein AS; Lawson DA; Teitell MA; Witte ON
    Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12465-70. PubMed ID: 19592505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular aspects of prostate cancer: recent data from the literature].
    Camparo P; Vieillefond A
    Bull Cancer; 2007 Jul; 94(7 Suppl):F77-88. PubMed ID: 17845997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.
    Longoni N; Sarti M; Albino D; Civenni G; Malek A; Ortelli E; Pinton S; Mello-Grand M; Ostano P; D'Ambrosio G; Sessa F; Garcia-Escudero R; Thalmann GN; Chiorino G; Catapano CV; Carbone GM
    Cancer Res; 2013 Jul; 73(14):4533-47. PubMed ID: 23687337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
    Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
    Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.
    Zoma M; Curti L; Shinde D; Albino D; Mitra A; Sgrignani J; Mapelli SN; Sandrini G; Civenni G; Merulla J; Chiorino G; Kunderfranco P; Cacciatore A; Kokanovic A; Rinaldi A; Cavalli A; Catapano CV; Carbone GM
    Nat Commun; 2021 Jul; 12(1):4147. PubMed ID: 34230470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma.
    Camões MJ; Paulo P; Ribeiro FR; Barros-Silva JD; Almeida M; Costa VL; Cerveira N; Skotheim RI; Lothe RA; Henrique R; Jerónimo C; Teixeira MR
    PLoS One; 2012; 7(11):e49819. PubMed ID: 23185447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?
    Adler D; Lindstrot A; Ellinger J; Rogenhofer S; Buettner R; Perner S; Wernert N
    Mol Med Rep; 2012 Feb; 5(2):313-6. PubMed ID: 22038307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERG upregulation and related ETS transcription factors in prostate cancer.
    Rostad K; Mannelqvist M; Halvorsen OJ; Oyan AM; Bø TH; Stordrange L; Olsen S; Haukaas SA; Lin B; Hood L; Jonassen I; Akslen LA; Kalland KH
    Int J Oncol; 2007 Jan; 30(1):19-32. PubMed ID: 17143509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
    Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
    Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
    Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
    Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oncogenic role of the ETS transcription factors MEF and ERG.
    Sashida G; Bazzoli E; Menendez S; Liu Y; Nimer SD
    Cell Cycle; 2010 Sep; 9(17):3457-9. PubMed ID: 20814243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.
    Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A
    BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
    Chen Y; Chi P; Rockowitz S; Iaquinta PJ; Shamu T; Shukla S; Gao D; Sirota I; Carver BS; Wongvipat J; Scher HI; Zheng D; Sawyers CL
    Nat Med; 2013 Aug; 19(8):1023-9. PubMed ID: 23817021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
    Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
    Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.